Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Splits AMG-706/Avastin Head-To-Head NSCLC Study Into Two Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

One trial will compare the multi-VEGF agent with Avastin in non-squamous non-small cell lung cancer and the second will study AMG-706’s effect in all non-small cell carcinoma patients.

You may also be interested in...



AMG-706 Comparison To Avastin Is Critical To Commercial Success, Amgen Says

Amgen reiterates need to compare the investigational oncologic to Avastin after changing its Phase III clinical program in April.

AMG-706 Comparison To Avastin Is Critical To Commercial Success, Amgen Says

Amgen reiterates need to compare the investigational oncologic to Avastin after changing its Phase III clinical program in April.

Genentech Aims To Extend Avastin Duration Of Use

Physicians have been treating first-line colorectal cancer patients for less time than the product was used for in clinical trials, Exec VP Clark says.

Topics

UsernamePublicRestriction

Register

PS064031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel